The fact that a pooled population of allogeneic BMMSCs could elicit pain reduction and cartilage regeneration in a preclinical model of OA coupled with the safety profile observed in human patients with a positive trend in pain reduction (in one of the cell doses tested) warrants further study in a large number of patients to investigate the therapeutic role of Stempeucel® in cartilage regeneration in OA patients.
← all excerpts
Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel®): preclinical and clinical trial in osteoarthritis of the knee joint.
1
—
—